Teladoc: Reiterating Our Speculative Buy As It Held Firm

Jun. 20, 2022 5:59 AM ETTeladoc Health, Inc. (TDOC)4 Comments4 Likes


  • This is a dedicated price action analysis of Teladoc stock. We observed that TDOC has been consolidating firmly after its post-earnings sell-off.
  • TDOC outperformed the market since our April update, increasing its near-term support's resilience. However, we have not observed a bear trap to help reverse its bearish bias.
  • Our reverse cash flow valuation model indicates a more reasonable valuation for Teladoc. However, it's still not undervalued.
  • We reiterate our Speculative Buy rating on TDOC stock.
  • I do much more than just articles at Ultimate Growth Investing: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Female healthcare professional

Solskin/DigitalVision via Getty Images

Price Action Thesis

We follow up with our post-FQ1 article on Teladoc Health, Inc. (NYSE:TDOC) stock, as we observed some significant developments in its price action structure over the past two months.

As a reminder, we cautioned investors against adding exposure before the release of its FQ1 earnings card, as we were concerned that Teladoc's estimates were too optimistic. However, its post-earnings sell-off led us to re-rate TDOC stock, as we thought it looked reasonable as a speculative opportunity.

Our price action analysis suggests TDOC stock is still undergirded by its April/May bottom. However, a bear trap price action to help stymie its bearish bias remains elusive.

Our reverse cash flow valuation analysis indicates that a speculative opportunity in TDOC stock is still reasonable at the current levels.

Accordingly, we reiterate our Speculative Buy opportunity in TDOC stock.

Digestion From Double Top Bull Trap Almost Complete

TDOC price chart (monthly)

TDOC price chart (monthly) (TradingView)

Investors must be wary of such double top bull traps, as seen in TDOC monthly chart above. We have enunciated in several articles that these potent bull traps often provide early warning signals to investors on the market's next massive move: rapid liquidation.

Notably, the double top occurred in February 2021, indicating the market's assessment of an overvalued TDOC stock. Unfortunately, we had not paid sufficient attention to its price action structure and missed its double top. As a result, it led to several poor calls on TDOC, as we ignored the warning from the market.

TDOC price chart (weekly)

TDOC price chart (weekly) (TradingView)

A series of subsequent bull traps corroborated its bearish bias after the initial rapid sell-off from its double top. Therefore, the market has astutely digested its rapid gains from 2020-21, drawing dip-buyers into those traps.

Notably, the capitulation move post-FQ1 in April was significant, leading to the formation of its near-term support. Moreover, the market rejected another sell-off in May as selling pressure was absorbed in TDOC stock.

However, a subtle bull trap in June helped form its near-term resistance. Therefore, investors are urged to add exposure close to its near-term support and avoid buying close to its near-term resistance.

Notwithstanding, we have not observed a significant bear trap price action signal that could indicate a potential reversal in its bearish bias. Therefore, the critical risk to its current consolidation phase leading to another sell-off remains. As a result, we urge investors to implement an appropriate stop-loss risk management strategy to prevent outsized drawdowns.

TDOC Valuation Is More Reasonable - But Not Undervalued

Teladoc revenue change % and adjusted EBITDA change % consensus estimates

Teladoc revenue change % and adjusted EBITDA change % consensus estimates (S&P Cap IQ)

Teladoc's massive revenue growth was clearly unsustainable, and the market's forward-looking ability from its double top bull trap in February 2021 was prescient.

However, its revenue growth is expected to reach a nadir in FY22 before normalizing. Furthermore, its adjusted EBITDA is estimated to recover from FY23, as Teladoc laps much easier comps from FY22's disaster.

Teladoc FCF margins % consensus estimates

Teladoc FCF margins % consensus estimates (S&P Cap IQ)

Furthermore, its free cash flow (FCF) profitability is also estimated to recover from FY23, undergirding its valuations. Notwithstanding, the company remains unprofitable on an adjusted and GAAP EPS through FY24, which could affect investors' sentiments on a potential re-rating.

Stock TDOC
Current market cap $4.94B
Hurdle rate (CAGR) 20%
Projection through CQ2'26
Required FCF yield in CQ2'26 3.5%
Assumed TTM FCF margin in CQ2'26 7.6%
Implied TTM revenue by CQ2'26 $4.72B

TDOC stock reverse cash flow valuation model. Data source: S&P Cap IQ, author

We used a hurdle rate appropriate for a growth stock but lower than its high-growth peers, given its slowing revenue growth. Therefore, we applied a higher FCF yield requirement of 3.5%, which is higher than its current NTM FCF yield of 2.96%.

However, we used a more conservative FCF margin of 7.6%, which is lower than its FY24 estimate of 9.3%, given Teladoc's uneven FCF profitability.

As a result, we require Teladoc to deliver a TTM revenue of $4.72B by CQ2'26. The revised consensus estimates indicate that Teladoc could post revenue of $3.48B in FY24.

Consequently, it requires Teladoc to post a revenue CAGR of 22.5% from FY24-CQ2'26. We think it's still a little aggressive but achievable if Teladoc executes well.

Is TDOC Stock A Buy, Sell, Or Hold?

We reiterate our Speculative Buy opportunity in TDOC stock. TDOC has outperformed the market since our re-rating in April. Therefore, the potential for a bottoming process at the current levels is increasing.

Notwithstanding, we emphasize that we have not observed a bear trap price action that could help reverse its bearish momentum. Therefore, the potential for another sell-off before creating its bear trap remains a critical risk to our price action thesis.

Our valuation analysis suggests that TDOC stock seems more reasonable now but not undervalued.

Therefore, we urge investors to apply appropriate risk management strategies to minimize the potential for large drawdowns.

Do you want to buy only at the right entry points for your growth stocks?

We help you to pick lower-risk entry points, ensuring you are able to capitalize on them with a higher probability of success and profit on their next wave up. Your membership also includes:

  • 24/7 access to our model portfolios

  • Daily Tactical Market Analysis to sharpen your market awareness and avoid the emotional rollercoaster

  • Access to all our top stocks and earnings ideas

  • Access to all our charts with specific entry points

  • Real-time chatroom support

  • Real-time buy/sell/hedge alerts

Sign up now for a Risk-Free 14-Day free trial!

This article was written by

JR Research profile picture
Sifting through the ultimate growth stocks for your portfolio

I'm Jere Wang, the lead writer and founder of JR Research and Ultimate Growth Investing Marketplace service. Our team is committed to bringing more clarity to investors in their investment decisions.

Our marketplace service focuses on a price-action-based approach to growth and technology stocks, supported by fundamental analysis. In addition, our general SA site discusses stocks from various sectors and industries. 

Our discussion mainly focuses on a short- to medium-term thesis. While we hold stocks for the long-term, we also use appropriate opportunities to benefit from short- to medium-term swings, leveraging long (directionally bullish) or short (directionally bearish) set-ups. 

My LinkedIn:


Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.